Flt3 ligand does not differentiate between Parkinsonian disorders.

Research output: Contribution to journalArticle

Abstract

Differential diagnosis of parkinsonian disorders is challenging because of overlapping symptoms, especially during early stages of disease. No validated biomarkers are available for early and accurate diagnosis of multiple system atrophy and other parkinsonian disorders. It has been reported that flt3 ligand levels in cerebrospinal fluid could clearly differentiate patients with Parkinson's disease from patients with multiple system atrophy, with 99% sensitivity and 95% specificity.

Details

Authors
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Neurology
Original languageEnglish
Pages (from-to)1319-1322
JournalMovement Disorders
Volume29
Issue number10
Publication statusPublished - 2014
Publication categoryResearch
Peer-reviewedYes